Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery

References

• Tighe AP, Schiavo G. Botulinum neurotoxins: mechanism of action. Toxicon 67, 87–93 (2013).
   PubMed Web of Science ®Google Scholar
• Montal M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 79, 591–617 (2010).
   PubMed Web of Science ®Google Scholar
• Dover N, Barash JR, Hill KK, Xie G, Arnon SS. Molecular characterization of a novel botulinum neurotoxin type H gene. J. Infect. Dis. doi:10.1093/infdis/jit450 (2013) ( Epub ahead of print).
   PubMedGoogle Scholar
• Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285(8), 1059–1070 (2001).
   PubMed Web of Science ®Google Scholar
• Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc. Natl Acad. Sci. USA 102(28), 9984–9989 (2005).
   PubMed Web of Science ®Google Scholar
• Hakami RM, Ruthel G, Stahl AM, Bavari S. Gaining ground: assays for therapeutics against botulinum neurotoxin. Trends Microbiol. 18(4), 164–172 (2010).
   PubMedGoogle Scholar
• Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. The evolving field of biodefence: therapeutic developments and diagnostics. Nat. Rev. Drug Discov. 4(4), 281–297 (2005).
   PubMed Web of Science ®Google Scholar
• Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins 4(10), 913–939 (2012).
   PubMedGoogle Scholar
• Pellett S. Learning from the past: historical aspects of bacterial toxins as pharmaceuticals. Curr. Opin. Microbiol. 15(3), 292–299 (2012).
   PubMed Web of Science ®Google Scholar
• Carruthers A, Carruthers J. Botulinum toxin products overview. Skin Therapy Lett. 13(6), 1–4 (2008).
   PubMedGoogle Scholar
• Schenone M, Dancik V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9(4), 232–240 (2013).
   PubMed Web of Science ®Google Scholar
• Schmidt JJ, Stafford RG, Millard CB. High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Anal. Biochem. 296(1), 130–137 (2001).
   PubMed Web of Science ®Google Scholar
• Burnett JC, Schmidt JJ, Stafford RG et al. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Commun. 310(1), 84–93 (2003).
   PubMed Web of Science ®Google Scholar
• Pellett S. Progress in cell based assays for botulinum neurotoxin detection. Curr. Top. Microbiol. Immunol. 364, 257–285 (2013).
   PubMed Web of Science ®Google Scholar
• Lee JA, Chu S, Willard FS et al. Open innovation for phenotypic drug discovery: The PD2 assay panel. J. Biomol. Screen. 16(6), 588–602 (2011).
   PubMedGoogle Scholar
• Swinney DC, Anthony J. How were new medicines discovered? Nat. Rev. Drug Discov. 10(7), 507–519 (2011).
   PubMed Web of Science ®Google Scholar
• Kalandakanond S, Coffield JA. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J. Pharmacol. Exp. Ther. 296(3), 980–986 (2001).
   PubMedGoogle Scholar
• Apland JP, Adler M, Oyler GA. Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25. J. Protein Chem. 22(2), 147–153 (2003).
   PubMedGoogle Scholar
• Blasi J, Chapman ER, Link E et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365(6442), 160–163 (1993).
   PubMed Web of Science ®Google Scholar
• Apland JP, Biser JA, Adler M et al. Peptides that mimic the carboxy-terminal domain of SNAP-25 block acetylcholine release at an Aplysia synapse. J. Appl. Toxicol. 19(Suppl. 1), S23–S26 (1999).
   PubMedGoogle Scholar
• Bajohrs M, Rickman C, Binz T, Davletov B. A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO Rep. 5(11), 1090–1095 (2004).
   PubMedGoogle Scholar
• Pellett S, Tepp WH, Toth SI, Johnson EA. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J. Pharmacol. Toxicol. Methods 61(3), 304–310 (2010).
   PubMed Web of Science ®Google Scholar
• Nuss JE, Ruthel G, Tressler LE et al. Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J. Biomol. Screen. 15(1), 42–51 (2010).
   PubMedGoogle Scholar
• Sheridan RE, Smith TJ, Adler M. Primary cell culture for evaluation of botulinum neurotoxin antagonists. Toxicon 45(3), 377–382 (2005).
   PubMed Web of Science ®Google Scholar
• Coffield JA, Yan X. Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons. J. Pharmacol. Exp. Ther. 330(1), 352–358 (2009).
   PubMed Web of Science ®Google Scholar
• Stahl AM, Ruthel G, Torres-Melendez E et al. Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. J. Biomol. Screen. 12(3), 370–377 (2007).
   PubMedGoogle Scholar
• Dong M, Tepp WH, Johnson EA, Chapman ER. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc. Natl Acad. Sci. USA 101(41), 14701–14706 (2004).
   PubMed Web of Science ®Google Scholar
• Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 581(25), 4803–4808 (2007).
   PubMed Web of Science ®Google Scholar
• Pellett S, Du ZW, Pier CL et al. Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem. Biophys. Res. Commun. 404(1), 388–392 (2010).
   PubMedGoogle Scholar
• Whitemarsh RC, Strathman MJ, Chase LG et al. Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol. Sci. 126(2), 426–435 (2012).
   PubMed Web of Science ®Google Scholar
• McNutt P, Celver J, Hamilton T, Mesngon M. Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research. Biochem. Biophys. Res. Commun. 405(1), 85–90 (2011).
   PubMed Web of Science ®Google Scholar
• Kiris E, Nuss JE, Burnett JC et al. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res. 6(3), 195–205 (2011).
   PubMed Web of Science ®Google Scholar
• Grumelli C, Verderio C, Pozzi D et al. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 26(5), 761–767 (2005).
   PubMedGoogle Scholar
• Basavanna U, Muruvanda T, Brown EW, Sharma SK. Development of a cell-based functional assay for the detection of clostridium botulinum neurotoxin types A and E. Int. J. Microbiol. 2013, 593219 (2013).
   PubMedGoogle Scholar
• Eubanks LM, Hixon MS, Jin W et al. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc. Natl Acad. Sci. USA 104(8), 2602–2607 (2007).
   PubMed Web of Science ®Google Scholar
• Yowler BC, Kensinger RD, Schengrund CL. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 277(36), 32815–32819 (2002).
   PubMed Web of Science ®Google Scholar
• Tsukamoto K, Arimitsu H, Ochi S et al. P19 embryonal carcinoma cells exhibit high sensitivity to botulinum type C and D/C mosaic neurotoxins. Microbiol. Immunol. 56(10), 664–672 (2012).
   PubMedGoogle Scholar
• Purkiss JR, Friis LM, Doward S, Quinn CP. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology 22(4), 447–453 (2001).
   PubMed Web of Science ®Google Scholar
• Hale M, Oyler G, Swaminathan S, Ahmed SA. Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J. Biol. Chem. 286(3), 1802–1811 (2011).
   PubMed Web of Science ®Google Scholar
• Fernandez-Salas E, Wang J, Molina Y et al. Botulinum neurotoxin serotype a specific cell-based potency assay to replace the mouse bioassay. PLoS ONE 7(11), e49516 (2012).
   PubMed Web of Science ®Google Scholar
• Tegenge MA, Bohnel H, Gessler F, Bicker G. Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A. Cell. Mol. Neurobiol. 32(6), 1021–1029 (2012).
   PubMed Web of Science ®Google Scholar
• Whitemarsh RC, Pier CL, Tepp WH, Pellett S, Johnson EA. Model for studying Clostridium botulinum neurotoxin using differentiated motor neuron-like NG108-15 cells. Biochem. Biophys. Res. Commun. 427(2), 426–430 (2012).
   PubMedGoogle Scholar
• Hong WS, Young EW, Tepp WH, Johnson EA, Beebe DJ. A microscale neuron and schwann cell coculture model for increasing detection sensitivity of botulinum neurotoxin type a. Toxicol. Sci. 134(1), 64–72 (2013).
   PubMed Web of Science ®Google Scholar
• Restani L, Giribaldi F, Manich M et al. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog. 8(12), e1003087 (2012).
   PubMed Web of Science ®Google Scholar
• Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38(2), 245–258 (2000).
   PubMed Web of Science ®Google Scholar
• Sun S, Suresh S, Liu H et al. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe 10(3), 237–247 (2011).
   PubMedGoogle Scholar
• Dong M, Yeh F, Tepp WH et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312(5773), 592–596 (2006).
   PubMed Web of Science ®Google Scholar
• Verderio C, Grumelli C, Raiteri L et al. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8(2), 142–153 (2007).
   PubMedGoogle Scholar
• Holtje M, Schulze S, Strotmeier J et al. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons. Toxicon 75, 108–121 (2013).
   PubMedGoogle Scholar
• Kroken AR, Karalewitz AP, Fu Z, Kim JJ, Barbieri JT. Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons. J. Biol. Chem. 286(30), 26828–26837 (2011).
   PubMedGoogle Scholar
• Keller JE, Cai F, Neale EA. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43(2), 526–532 (2004).
   PubMed Web of Science ®Google Scholar
• Wiese S, Herrmann T, Drepper C et al. Isolation and enrichment of embryonic mouse motoneurons from the lumbar spinal cord of individual mouse embryos. Nat. Protoc. 5(1), 31–38 (2009).
   PubMedGoogle Scholar
• Camu W, Henderson CE. Purification of embryonic rat motoneurons by panning on a monoclonal antibody to the low-affinity NGF receptor. J. Neurosci. Methods 44(1), 59–70 (1992).
   PubMedGoogle Scholar
• Miles GB, Yohn DC, Wichterle H et al. Functional properties of motoneurons derived from mouse embryonic stem cells. J. Neurosci. 24(36), 7848–7858 (2004).
   PubMedGoogle Scholar
• Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell 110(3), 385–397 (2002).
   PubMed Web of Science ®Google Scholar
• Wichterle H, Peljto M, Nedelec S. Xenotransplantation of embryonic stem cell-derived motor neurons into the developing chick spinal cord. Methods Mol. Biol. 482, 171–183 (2009).
   PubMedGoogle Scholar
• Wichterle H, Peljto M. Differentiation of mouse embryonic stem cells to spinal motor neurons. Curr. Protoc. Stem Cell Biol. Chapter 1, unit 1H.1.1–1H.1.9 (2008).
   Google Scholar
• Soundararajan P, Miles GB, Rubin LL, Brownstone RM, Rafuse VF. Motoneurons derived from embryonic stem cells express transcription factors and develop phenotypes characteristic of medial motor column neurons. J. Neurosci. 26(12), 3256–3268 (2006).
   PubMedGoogle Scholar
• Harper JM, Krishnan C, Darman JS et al. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc. Natl Acad. Sci. USA 101(18), 7123–7128 (2004).
   PubMedGoogle Scholar
• Adler S, Bicker G, Bigalke H et al. The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. Altern. Lab. Anim. 38(4), 315–330 (2010).
   PubMed Web of Science ®Google Scholar
• Seok J, Warren HS, Cuenca AG et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110(9), 3507–3512 (2013).
   PubMed Web of Science ®Google Scholar
• McNeish J, Roach M, Hambor J et al. High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors. J. Biol. Chem. 285(22), 17209–17217 (2010).
   PubMedGoogle Scholar
• Li XJ, Hu BY, Jones SA et al. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells 26(4), 886–893 (2008).
   PubMedGoogle Scholar
• Hu BY, Zhang SC. Directed differentiation of neural-stem cells and subtype-specific neurons from hESCs. Methods Mol. Biol. 636, 123–137 (2009).
   Google Scholar
• Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3(6), 637–648 (2008).
   PubMed Web of Science ®Google Scholar
• Dimos JT, Rodolfa KT, Niakan KK et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321(5893), 1218–1221 (2008).
   PubMed Web of Science ®Google Scholar
• Lee H, Shamy GA, Elkabetz Y et al. Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells 25(8), 1931–1939 (2007).
   PubMed Web of Science ®Google Scholar
• Singh Roy N, Nakano T, Xuing L et al. Enhancer-specified GFP-based FACS purification of human spinal motor neurons from embryonic stem cells. Exp. Neurol. 196(2), 224–234 (2005).
   PubMed Web of Science ®Google Scholar
• Nizzardo M, Simone C, Falcone M et al. Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells. Cell. Mol. Life Sci. 67(22), 3837–3847 (2010).
   PubMed Web of Science ®Google Scholar
• Amoroso MW, Croft GF, Williams DJ et al. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J. Neurosci. 33(2), 574–586 (2013).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663–676 (2006).
   PubMed Web of Science ®Google Scholar
• Marchetto MC, Brennand KJ, Boyer LF, Gage FH. Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises. Hum. Mol. Genet. 20(R2), R109–R115 (2011).
   PubMedGoogle Scholar
• Boland MJ, Hazen JL, Nazor KL et al. Adult mice generated from induced pluripotent stem cells. Nature 461(7260), 91–94 (2009).
   PubMed Web of Science ®Google Scholar
• Zhao XY, Li W, Lv Z et al. Viable fertile mice generated from fully pluripotent iPS cells derived from adult somatic cells. Stem Cell Rev. 6(3), 390–397 (2010).
   Google Scholar
• Narsinh KH, Plews J, Wu JC. Comparison of human induced pluripotent and embryonic stem cells: fraternal or identical twins? Mol. Ther. 19(4), 635–638 (2011).
   PubMedGoogle Scholar
• Hu BY, Weick JP, Yu J et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 107(9), 4335–4340 (2010).
   PubMed Web of Science ®Google Scholar
• Feng Q, Lu SJ, Klimanskaya I et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 28(4), 704–712 (2010).
   PubMed Web of Science ®Google Scholar
• Narsinh KH, Sun N, Sanchez-Freire V et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J. Clin. Invest. 121(3), 1217–1221 (2011).
   PubMedGoogle Scholar
• Sandoe J, Eggan K. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat. Neurosci. 16(7), 780–789 (2013).
   PubMed Web of Science ®Google Scholar
• Bar-Nur O, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 9(1), 17–23 (2011).
   PubMed Web of Science ®Google Scholar
• Bock C, Kiskinis E, Verstappen G et al. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144(3), 439–452 (2011).
   PubMed Web of Science ®Google Scholar
• Lister R, Pelizzola M, Kida YS et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471(7336), 68–73 (2011).
   PubMed Web of Science ®Google Scholar
• Boulting GL, Kiskinis E, Croft GF et al. A functionally characterized test set of human induced pluripotent stem cells. Nat. Biotechnol. 29(3), 279–286 (2011).
   PubMed Web of Science ®Google Scholar
• Marchetto MC, Muotri AR, Mu Y et al. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 3(6), 649–657 (2008).
   PubMed Web of Science ®Google Scholar
• Yang N, Ng YH, Pang ZP, Sudhof TC, Wernig M. Induced neuronal cells: how to make and define a neuron. Cell Stem Cell 9(6), 517–525 (2011).
   PubMedGoogle Scholar
• Son EY, Ichida JK, Wainger BJ et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 9(3), 205–218 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pak C, Han Y et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78(5), 785–798 (2013).
   PubMed Web of Science ®Google Scholar
• Buchser W, Collins M, Garyantes T et al. Assay development guidelines for image-based high content screening, high content analysis and high content imagingM. In: Assay Guidance Manual. Sittampalam GS, Gal-Edd N, Arkin M et al. (Eds). Bethesda, MD, USA (2004)
   Google Scholar
• Eglen RM, Reisine T. New insights into GPCR function: implications for HTS. Methods Mol. Biol. 552, 1–13 (2009).
   PubMedGoogle Scholar
• de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl Acad. Sci. USA 96(6), 3200–3205 (1999).
   PubMed Web of Science ®Google Scholar
• Bickle M. The beautiful cell: high-content screening in drug discovery. Anal. Bioanal. Chem. 398(1), 219–226 (2010).
   PubMed Web of Science ®Google Scholar
• Honer WG, Falkai P, Bayer TA et al. Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb. Cortex 12(4), 349–356 (2002).
   PubMedGoogle Scholar
• Degorce F, Card A, Soh S et al. HTRF: a technology tailored for drug discovery - a review of theoretical aspects and recent applications. Curr. Chem. Genomics 3, 22–32 (2009).
   PubMedGoogle Scholar
• Bakry N, Kamata Y, Simpson LL. Lectins from triticum vulgaris and limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin. J. Pharmacol. Exp. Ther. 258(3), 830–836 (1991).
   PubMed Web of Science ®Google Scholar
• Fischer A, Nakai Y, Eubanks LM et al. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc. Natl Acad. Sci. USA 106(5), 1330–1335 (2009).
   PubMed Web of Science ®Google Scholar